Alopecia areata impacts nearly 7 million Americans, yet severe cases long lacked FDA-approved treatments until 2023, when Pfizer’s LITFULO (ritlecitinib) became an oral medication approved for the condition. The drug targets autoimmune inflammation disrupting hair follicles, providing a new option for patients who have exhausted other therapies.
Alopecia areata is more than a cosmetic issue—it’s a chronic autoimmune disease where the immune system attacks hair follicles, causing unpredictable hair loss. Unlike stress-related hair loss, alopecia areata involves persistent inflammation that can flare without warning.
Traditional treatments, such as steroid pills, creams, or injections, suppress immune activity but weren’t designed for alopecia areata. Many patients experience only temporary results, with side effects like skin thinning or weight gain. Wigs or hairpieces offer help for some, but they come with challenges: discomfort, itchiness, and practical difficulties like swimming or intimacy.
LITFULO works differently by binding to select proteins within immune cells, which can reduce immune activation and the inflammatory signaling involved in alopecia areata. In clinical trials, 23 percent of people taking LITFULO saw 80 percent or more scalp hair coverage in just under 6 months versus 1.6 percent on placebo. However, regrowth takes time. “It could take six months before you see regrowth,” Dr. Soung says. “The waiting can be difficult, but hair regrowth takes time.”
Before starting LITFULO, patients must find a specialist experienced in alopecia areata, as not all dermatologists treat it. Pfizer’s Dermatologist Finder tool helps locate qualified providers. A dermatologist will discuss the screening and monitoring needed before and during treatment, as well as your medical history including any medications you are taking.
Dr. Soung advises that treatment decisions should be collaborative. “When a patient comes to see me, I ask them to tell me about any concerns they have with their alopecia areata and what their treatment goals are,” she says. “It really gets to how severe it is and how I can help you.” For some, LITFULO may be the missing piece in their treatment plan, while for others, it may not be the right fit.
The medication’s approval marks a shift in alopecia areata care, moving beyond off-label steroid use or experimental therapies with limited evidence. Now, there’s an FDA-approved oral option for the disease. However, it isn’t a cure, it manages symptoms, and side effects require careful oversight. “I think it’s been a really helpful addition to my toolbox and a medication with the potential to help patients regrow their hair,” Dr. Soung says. “I want to give patients options. Understanding their concerns and how severe alopecia areata has impacted them helps us explore treatment options, like LITFULO.”
LITFULO does have some potential risks. LITFULO may cause serious side effects, including serious infections, increased risk of death, cancer and immune system problems, major cardiovascular events, blood clots, and allergic reactions. Learn more about these and other serious risks in the Important Safety Information below.
